Background: Second-and third-generation chemotherapy protocols for the treatment of aggressive non-Hodgkin's lymphomas (NHL) have considerable, and age-related, toxic effects. In addition, they do not seem to prolong overall survival in comparison to standard CHOP chemotherapy. In this phase II study we investigated the feasibility and efficacy of the addition of etoposide to the conventional CHOP regimen. Results: The overall response rate was 84%, with 70% complete and 14% partial responses. The predicted three-and fiveyear survivals for the group as a whole were 60% and 53%,
Introduction
The introduction of multiagent chemotherapy has radically improved the prognosis of patients with high-grade malignant non-Hodgkin's lymphoma (NHL). More than two decades ago McKelvey et al. [1] reported on the successful use of the first-generation regimen, CHOP, combining cyclophosphamide, doxorubicin, vincristine, and prednisone. Durable complete remissions were seen in 30% of patients. Since then the results of studies employing a variety of second-and third-generation chemotherapeutic regimens have indicated that longterm complete responses can be achieved in 45% to 65% of patients [2] [3] [4] [5] [6] . Most of these prospective studies have been performed in single institutions and so far the results have contrasted with those of prospective randomised trials comparing first-with second-and third-generation chemotherapy programs [7] [8] [9] [10] . Furthermore, the toxicity of these newer drug combinations is considerable and patients frequently require institutional care. It is also well recognised that most patients > 60 years of age have a poor tolerance for this type of intensive chemotherapy, primarily because of the attendant severe myelosuppression and high-dose anthracycline and vinca alkaloid-related toxicity [4, 5, 11] . Thus, despite their poor prognoses, elderly patients with or without concurrent disorders are frequently excluded from trials using intensive regimens.
Among the drugs which are effective in the treatment of aggressive NHL, etoposide, together with doxorubicin and cyclophosphamide, has become the most firmly established. Its efficacy as a single agent has been documented [12] , also in refractory NHL [13] . However, most of the patients in studies adding etoposide to conventional CHOP chemotherapy have had refractory or relapsed disease. Furthermore, in studies where CHOP/ etoposide has been given up-front, modifications of the CHOP component have been introduced [14] [15] [16] [17] [18] . Thus, it seemed logical to explore the addition of etoposide (given over three days) to standard CHOP chemotherapy with its well-established efficacy and limited toxicity in an effort to increase its anti-neoplastic effect in aggressive NHL. This regimen, intended for outpatient use, looked promising in relapsing patients [19] . We report the therapeutic efficacy, toxicity and risk factors in previously untreated patients with aggressive NHL receiving CHOP-E. /l > 6 days) were recorded after the preceding course of chemotherapy. Treatment was repeated every three weeks. Patients were restaged after four courses or earlier if clinically indicated and after completion of the therapy. Patients with a response less than partial remission (PR) after four courses were excluded from further CHOP-E chemotherapy and were treated according to the discretion of the investigator. However, most non-responding patients were given the MIME regimen [22] . No antiviral, antibacterial or antifungal prophylaxis was used. Involved field radiation was given for bulky disease at presentation.
The use of hematopoietic growth factors was not restricted and 29% of patients received G-or GM-CSF after one or several chemotherapy courses. Growth factors were predominantly given to patients with a prior chemotherapy-related infectious complication, often in combination with a CHOP-E dose attenuation.
Eleven patients received high-dose chemotherapy with or without total body irradiation and blood stem cell or bone marrow transplantation (nine autologous and two allogeneic; one patient in first CR and 10 patients in second CR).
Response evaluation
At restaging, complete remission (CR) was defined as the complete disappearance of all clinical disease manifestations and the reversal of all previously abnormal investigations. All patients achieving CR received two to four additional CHOP-E cycles. Partial remission (PR) was denned as a reduction of > 50% of all measurable tumours without new lesions. Response less than PR, but not fulfilling the criteria for progressive disease (PD) was defined as stable disease (SD). PD was defined as an increase in size (> 25%) of one or more measurable lesions or the appearance of new lesions.
Patients and methods

Patients
A total of 132 patients ( > 16 years) with previously untreated highgrade NHL were included. The clinical characteristics of the patients receiving CHOP-E are listed in Table 1 . The median age was 54 years (range 17-85) with 50 patients (38%) being >60 years. The median follow-up of surviving patients was 53 months (range 12+-95+).
The diagnosis was based on morphological and immunohistochemical examination of tumour biopsy material. For clinical reasons the diagnostic material was limited in a few patients to several needle aspiration biopsies. Diagnostic specimens were classified according to the updated Kiel classification [20] . The pre-treatment evaluation consisted of physical examination, hematological and chemical surveys, chest X-ray, computerised tomography of the abdomen and pelvis and when clinically indicated of the chest, and bone marrow biopsy. None of the patients underwent staging laparotomy. Bulky disease was defined as a tumour mass > 10 cm. The Ann Arbor staging classification was used [21] . Toxicity and performance status were assessed by Statistics Overall survival (OS) and disease free-survival (DFS) were calculated according to the method of Kaplan and Meier [23] . OS was calculated from the start of therapy and DFS from the onset of CR to date of relapse; two patients who died without evidence of lymphoma (myocardial infarction and septicemia not related to treatment) were censored at the time of death. Two emigrating patients were censored at the time of their last follow-up. The log-rank test was used to assess the significance of differences in OS and DFS [24] . A non-parametric chisquare test was used for 2 x 2 tables.
Results
Response to therapy
Ninety-two patients (70%) achieved CR and 14% PR, for an overall response rate of 84%, while 16% failed to (22) 4 (8) 14 (17) 10 (11) 8 (19) 4 (9) 13 (17) 1 (10) SD (%)
14 (10) 10 (10) 4(19) (14) 3 (6) 11 (14) 7 (8) 7 (16) 4 (9) 9 (12) 1 (10) PD (%)
4 (5) 4 (8) 1 (2) 7 (9) 2 (2) 6 (14) 1 (2) Abbreviations: CR -complete remission; PR -partial remission; SD -stable disease; PD -progressive disease. n P < 0.05.
respond or had progressive disease (Table 2 ). Fifty-seven of 92 CR patients (62%) received six to eight cycles of CHOP-E chemotherapy with no reduction in relative dose intensity. The CR rate was significantly lower in patients > 60 years (56% vs. 78% for younger patients; P < 0.05) and in patients with stage III-IV disease (60% vs. 84% for stage I-II patients; P < 0.05; Table 2 ).
Survival
The predicted three-and five-year OS for the entire CHOP-E group were 60% and 53%, respectively ( Figure 1 ). Patient survival according to the international prognostic factor index [25] is shown in Figure 2 . Stage III-IV patients had a significantly worse survival than patients with limited disease (I-II; P < 0.05; Table 2 ). The OS curve of stage I-II patients reached a plateau phase of about 65% at four years, in contrast to the slowly declining survival curve of patients with advanced disease. Performance status was excluded in this analysis (see under 'patients and methods'). Patients with elevated LDH (>8.0 ukat/1) had significantly shorter survivals than the remainder (P < 0.05) and patients >60 years tended to have worse survivals than younger patients (P -0.06). The predicted three-and five-year DFS for CR patients were 65% and 56%, respectively. DFS at five years were almost identical for patients < 60 years (56%, n = 64), patients ^ 60-< 70 years (63%, n = 19), and patients ^ 70 years (64%, n -9).
Toxicity
The toxic effects of chemotherapy are shown in Table 3 .
In general, neutropenia with infection was the major side effect of this regimen while other toxicities were modest. There were four therapy-related deaths (3%),
> m
Time (years) Figure I Overall survival of all patients calculated according to the ICaplan-Meier method [23] .
Time (years) Figure 2 . Comparison of overall survival between patients with 0-1 risk factors (n = 46), two risk factors (n = 28), three risk factors (n = 38) and four risk factors (n = 10), according to Shipp et al. [25] . three due to septicemia and one due to haemorrhage. Eighty-seven percent of patients developed leukopenia WHO grade 3-4 and one-third of the patients received antibiotic treatment for severe infection or neutropenic fever of unknown origin. Other severe toxicities, i.e. WHO grade 3-4, were infrequent; stomatitis (2%), diarrhoea (4%) neurotoxicity (2%) and liver toxicity (1%). No patient with a chemotherapy-related leukemia or other hematological malignancy was recorded during the study period. The majority (>80%) of chemotherapy courses were administered on an outpatient basis.
Discussion
New chemotherapeutic regimens for the treatment of aggressive NHL have frequently been introduced in recent years. The majority of them have included at least six different cytostatic drugs and the dose schedule of etoposide has been employed with wide variations. In view of the lack of cross-resistance between vincristine and etoposide [26, 27] and the efficacy of etoposide as a single drug in NHL [12, 13] , the addition of etoposide to the conventional CHOP regimen seemed to be a potential way to improve efficacy while maintaining toxicity at a tolerable level. Such attempts have been made in a restricted number of studies with variants of the CHOP-E regimen used in this study, reporting CR rates of 73%-87% in patients with aggressive NHL [14, 16, 18] . However, there are no available results from a strict comparison between CHOP and CHOP-E in this patient population.
The standard CHOP regimen with the addition of i.v. (day 1) and oral (day 2-3) etoposide used in the present study yielded a CR rate of 70% and predicted three-and five-year OS of 60% and 53%, respectively. If stage I patients (mainly with extranodal and/or bulky disease and/or advanced age) were excluded the corresponding survival figures were 57% and 49%. These survival rates may be compared with those of a similar study performed in the Nordic countries during the same time period in which patients with aggressive NHL were randomised to receive CHOP or MACOP-B. In the CHOP arm of this study including only stage II-IV patients (n -166; median age 51 years) the predicted three-and five-year OS were 60% and 56%, respectively (M. Jerkeman, personal communication).
Although this was not a randomized study it seems unlikely that CHOP-E chemotherapy as used here is superior to CHOP with regard to complete remission rate, disease-free or overall survival. One possible explanation for this suggested lack of improvement could be the fact that 42% of courses given to patients achieving CR were reduced by 25% or more and 14% of the patients received fewer than the initially planned six courses. The main reason for these dose and schedule modifications was myelosuppression (87% of courses WHO grade 3-4) with 33% of patients developing an infectious complication requiring hospital care. These results are in contrast to those recently presented by Bergman et al. [18] using a CHOP modification plus etoposide in aggressive NHL. In their patient population with the same median age (54 years) as the one in the present study only 7% of the chemotherapy courses were associated with severe infections despite the fact that both the doxorubicin and etoposide doses were considerably higher. Forty-five percent of their patients received hemopoietic growth factor support (only GM-CSF) compared to 29% of the patients in the present study (predominantly G-CSF) which could only partly explain the drastic difference in severe infections/septicemias. The distribution of risk factors [25] and their impact on treatment outcome were similar in the two series.
There were three deaths due to septicemia in our patient population which compares well with the results of other studies using CHOP in high-grade NHL [7, 10] . The addition of G-or GM-CSF to patients receiving chemotherapy for malignant NHL generally reduces the infection rate and duration of neutropenia. However, the use of growth factors does not produce any significant improvement with regard to dose intensity, CR rate or survival [28] [29] [30] . It is well established that patients > 60 years with high-grade malignant NHL present a high mortality rate from different causes, one of them being a greater risk of increased organ toxicity. Interestingly, the median age of the 43 patients (33%) who developed severe infectious complications requiring i.v. antibiotics was 55 years, i.e., not different from that of the series as a whole. However, there was a clear tendency to more frequent dose reductions (and reduced survival) in the age group above 65 years. The challenge to optimize treatment for the elderly patient with aggressive NHL remains and one important step would be the identification of the relatively few patients in this age group who can tolerate the toxicity of curative combination chemotherapy. It is hoped that the results of a large, recently closed, Nordic trial randomising patients (> 60 years) to CHOP or CNOP (N=mitoxantrone) chemotherapy with or without G-CSF support will add to our present knowledge in this respect.
In conclusion, CHOP-E, with the addition of etoposide for three days to conventional CHOP, does not seem to be more efficacious than CHOP alone. Myelosuppression was the most limiting toxicity. Although eagerly awaited, the results of a controlled randomised trial comparing CHOP with CHOP plus etoposide are not yet available. However, soon to be closed is one such large German study in which the impact of G-CSF and shorter time interval between courses will also be evaluated (M. Pfreundschuh, personal communication).
